Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 15/20 | 1.00 |
| ▸ | SRC | P12931 | 3/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.68 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.68 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.68 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.57 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.57 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.57 |
| ▸ | CSF1R | P07333 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31557251 | 1.00 | WEE1 (1.00) | WEE1SRCFGFR1FGFR4FGFR2 | |
| SCHEMBL14875763 | 0.94 | WEE1 (0.89) | WEE1SRCFGFR1FGFR4FGFR2 | |
| SCHEMBL31557174 | 0.94 | WEE1 (0.89) | WEE1SRCFGFR1FGFR4FGFR2 | |
| SCHEMBL31557201 | 0.92 | WEE1 (0.85) | WEE1SRCFGFR1FGFR4FGFR2 | |
| SCHEMBL14876117 | 0.92 | WEE1 (0.85) | WEE1SRCFGFR1FGFR4FGFR2 | |
| SCHEMBL16454982 | 0.91 | WEE1 (0.84) | WEE1SRCFGFR1FGFR4FGFR2 | |
| SCHEMBL16455014 | 0.91 | WEE1 (0.84) | WEE1SRCFGFR1FGFR4FGFR2 | |
| SCHEMBL31557302 | 0.91 | WEE1 (0.83) | WEE1SRCFGFR1FGFR4FGFR2 | |
| SCHEMBL14875643 | 0.91 | WEE1 (0.83) | WEE1SRCFGFR1FGFR4FGFR2 | |
| SCHEMBL14875677 | 0.90 | WEE1 (1.00) | WEE1SRCFGFR1FGFR4FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181239-B2 | Pyridopyrimidinone inhibitors of kinases | ABBVIE INC. (US) | 2015-11-10 | — | — | US | claimed |
| US-20130102590-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES | ABBVIE INC (US) | 2013-04-25 | — | — | US | claimed |
| US-9181239-B2 | Pyridopyrimidinone inhibitors of kinases | ABBVIE INC. (US) | 2015-11-10 | — | — | US | disclosed |
| WO-2015019037-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2015-02-12 | — | — | WO | disclosed |
| EP-2776434-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20130102590-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES | ABBVIE INC (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2013059485-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES | ABBVIE INC. (US) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102590-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES | WEE1, WEE2, CDK1 | WEE1 1/4885SRC 286/4885FGFR1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.